A multi-centre, post-marketing surveillance study of Vi polysaccharide–tetanus toxoid conjugate vaccine (Typbar TCV®) in India

A typhoid Vi capsular-polysaccharide tetanus toxoid conjugate vaccine (Typbar-TCV®) was recommended by the World Health Organization for use in children >6 months of age. The present post-marketing surveillance study was intended to assess the clinical safety of approximately 11 million doses of...

Full description

Bibliographic Details
Main Authors: Raghu Reddy, Bhargav Reddy, Vamshi Sarangi, Siddharth Reddy, Raches Ella, Krishna Mohan Vadrevu
Format: Article
Language:English
Published: Taylor & Francis Group 2022-01-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Online Access:http://dx.doi.org/10.1080/21645515.2021.1947761